Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses

The Lancet Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles